AbbVie ABBV continued its acquisition spree with the announcement of a definitive agreement to acquire private biotech Nimble ...
AbbVie is set to acquire privately held biotech, Nimble Therapeutics, for $200 million to strengthen its immunology pipeline.
The Nimble acquisition, which follows the $1.4 billion buy of Aliada Therapeutics in October, will help AbbVie rebuild and ...
AbbVie has agreed a $200 million-plus takeover deal with Roche spinout Nimble Therapeutics that will give it control of a ...
The acquisition includes Nimble's investigational candidate, an oral peptide IL23R inhibitor to treat psoriasis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback